

**Media Relations:**

Len Hall  
Allen & Caron Inc.  
(949) 474-4300  
[len@allencaron.com](mailto:len@allencaron.com)

**Investor Relations:**

Matt Clawson  
Allen & Caron Inc.  
(949) 474-4300  
[matt@allencaron.com](mailto:matt@allencaron.com)

## **BioLife Solutions Granted Japanese Biopreservation Patent**

### *Key Intellectual Property Related to Minimizing Biopreservation-Induced Cell Death*

**BOTHELL, Wash.**—November 18, 2009—BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has been granted a Japanese patent for an application that includes claims related to protecting cells from injury and death caused by cold temperatures used in biopreservation. The patent is titled “Inclusion of Apoptotic Regulators in Solutions for Cell Storage at Low Temperature,” and BioLife was previously granted US and European patent protection for this intellectual property.

Mike Rice, BioLife’s chairman and CEO, noted the new patent is a direct result of BioLife’s ongoing efforts to increase the value of its intellectual property portfolio and enable additional product and licensing revenue streams for BioLife. “In addition to this granted Japanese patent, two international Patent Cooperation Treaty (PCT) applications were recently published covering claim sets related to the collection, storage, transport, and banking of whole blood and also birth tissue including cord blood. I’m pleased that our research and development activities continue to produce discoveries and potential innovations in the biopreservation field.”

### **About BioLife Solutions, Inc:**

BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company’s proprietary HypoThermosol<sup>®</sup> and CryoStor<sup>™</sup> platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife’s cGMP products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife’s enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue viability and function. For more information please visit [www.biolifesolutions.com](http://www.biolifesolutions.com).

*This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions’ actual results to differ materially are discussed in the Company’s recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.*

###